

NOTICE OF DATE OF ANNUAL GENERAL MEETING AND OTHER RELEVANT DATES

Melbourne, Australia – 12 August 2026: Pursuant to ASX Listing Rule 3.13.1 Percheron Therapeutics Limited (ASX: PER) (**Percheron** or the **Company**) is pleased to advise the following details in relation to the Company's forthcoming Annual General Meeting (**AGM**).

Date and time for the AGM	Wednesday 7 October 2026 10:00am (AEDT)
Date of Notice of Meeting dispatch	Monday 7 September 2026
Last date for receipt of nomination as a Director	Wednesday 19 August 2026 5:00pm (AEST)

Any nominations must be received at the Company's registered office by no later than 5:00pm (AEST) Wednesday 19 August 2026.

Further details in relation to the AGM, including items of business to be voted upon by shareholders, and instructions on how shareholders may attend and vote at the meeting (including on how to appoint a proxy), will be provided in the Notice of Meeting (**NOM**). In accordance with section 110D (1) of the *Corporations Act 2001* (Cth), the Company will not be sending hard copies of the NOM to shareholders unless a shareholder has requested a hard copy. After dispatch, a copy of the NOM will be available on the Company's website at www.PercheronTx.com.

The Company looks forward to shareholder participation at this year's AGM.

~ ENDS ~

About Percheron Therapeutics Limited

Percheron Therapeutics Limited [ASX: PER | US OTC: PERCF] is a publicly listed biotechnology company focused on the development and commercialisation of novel therapies for oncology and rare diseases. The company's lead program is HMBD-002, a monoclonal antibody targeting the immune checkpoint regulator, VISTA. HMBD-002 has completed a phase I clinical trial in patients with advanced cancer, which has shown the drug to be generally safe and well-tolerated, and Percheron aims to commence further clinical trials in CY2026.

For more information, please contact info@PercheronTx.com.

This announcement has been authorised for release to the Australian Securities Exchange by Ms Deborah Ambrosini, Company Secretary, Percheron Therapeutics.
